Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJan Philipp BewersdorfRWRong WangLMLourdes Méndez

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows venetoclax may improve outcomes in post-MPN AML, highlighting treatment limitations.

Key Points

  • To evaluate the impact of novel AML treatments on outcomes in patients with post-MPN AML.
  • Retrospective analysis using Flatiron Health Research Database
  • Included patients diagnosed with post-MPN AML from 2014-2024
  • Grouped patients by treatment era (pre-VEN and post-VEN)
  • Compared treatment patterns and overall survival
  • Median overall survival for the cohort was 7.24 months
  • 66% of patients received lower-intensity therapy as first-line treatment
  • Better outcomes associated with male sex and higher socioeconomic status
  • HMA/VEN was the most common first-line regimen in the post-VEN era
  • Only 15% underwent allogeneic hematopoietic cell transplant

Cite This Study

Bewersdorf et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4cdhttps://doi.org/10.1182/blood-2025-721
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States2026 · 1 citations
  2. 2A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  3. 3Outcomes of low-intensity AML therapy based on treatment facility2025
  4. 4Outcomes of blast-phase MPN and JAK2, MPL, and CALRmutated de novo AML: A propensity score-adjusted cohort study.2024
  5. 5Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry2025